<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">27121262</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>04</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1365-2125</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>82</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2016</Year>
<Month>09</Month>
</PubDate>
</JournalIssue>
<Title>British journal of clinical pharmacology</Title>
<ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.</ArticleTitle>
<Pagination>
<MedlinePgn>728-38</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.12991</ELocationID>
<Abstract>
<AbstractText Label="AIM">The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.</AbstractText>
<AbstractText Label="METHODS">Eligible adults with advanced malignancies for which no further effective therapy was available received a single dose of ixazomib on day 1 of the pharmacokinetic cycle; patients with normal hepatic function, moderate hepatic impairment or severe hepatic impairment received 4 mg, 2.3 mg or 1.5 mg, respectively. Blood samples for single-dose pharmacokinetic characterization were collected over 336 h postdose. After sampling, patients could continue to receive ixazomib on days 1, 8 and 15 in 28-day cycles.</AbstractText>
<AbstractText Label="RESULTS">Of 48 enrolled patients (13, 15 and 20 in the normal, moderate and severe groups, respectively), 43 were pharmacokinetics-evaluable. Ixazomib was rapidly absorbed (median time to reach peak concentration was 0.95-1.5 h) and highly bound to plasma proteins, with a similar mean fraction bound (~99%) across the three groups. In patients with moderate/severe hepatic impairment (combined group), the geometric least squares mean ratios (90% confidence interval) for unbound and total dose-normalized area under the plasma concentration vs. time curve from time zero to the time of the last quantifiable concentration in reference to the normal hepatic function group were 1.27 (0.75, 2.16) and 1.20 (0.79, 1.82), respectively. Seven (15%) of the 48 patients experienced a grade 3 drug-related adverse event; there were no drug-related grade 4 adverse events.</AbstractText>
<AbstractText Label="CONCLUSIONS">In patients with moderate/severe hepatic impairment, unbound and total systemic exposures of ixazomib were 27% and 20% higher, respectively, vs. normal hepatic function. A reduced ixazomib starting dose of 3 mg is recommended for patients with moderate or severe hepatic impairment.</AbstractText>
<CopyrightInformation>© 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley &amp; Sons Ltd on behalf of The British Pharmacological Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Neeraj</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hanley</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Venkatakrishnan</LastName>
<ForeName>Karthik</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Perez</LastName>
<ForeName>Raymond</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>University of Kansas Clinical Research Center, Fairway, KS, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Norris</LastName>
<ForeName>Robin E</ForeName>
<Initials>RE</Initials>
<AffiliationInfo>
<Affiliation>University Hospitals of Cleveland, Cleveland, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Nemunaitis</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Mary Crowley Cancer Research Centers, Dallas, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Huyuan</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Qian</LastName>
<ForeName>Mark G</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Falchook</LastName>
<ForeName>Gerald</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Labotka</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Siqing</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>05</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Br J Clin Pharmacol</MedlineTA>
<NlmUniqueID>7503323</NlmUniqueID>
<ISSNLinking>0306-5251</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001896">Boron Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>71050168A2</RegistryNumber>
<NameOfSubstance UI="C548400">ixazomib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>TE7660XO1C</RegistryNumber>
<NameOfSubstance UI="D005998">Glycine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001896">Boron Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005998">Glycine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008107">Liver Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061988">Proteasome Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">hepatic impairment</Keyword>
<Keyword MajorTopicYN="Y">ixazomib</Keyword>
<Keyword MajorTopicYN="Y">phase 1 clinical trial</Keyword>
<Keyword MajorTopicYN="Y">proteasome inhibitor</Keyword>
<Keyword MajorTopicYN="Y">solid tumours</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2016</Year>
<Month>01</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2016</Year>
<Month>04</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27121262</ArticleId>
<ArticleId IdType="doi">10.1111/bcp.12991</ArticleId>
<ArticleId IdType="pmc">PMC5089614</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Oncol. 2008 Feb 1;26(4):563-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18235115</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Pharmacokinet. 1999 Nov;37(5):399-431</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10589374</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2014 Aug 14;124(7):1038-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24920586</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2010 Oct 10;28(29):4507-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20837947</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2012 Apr;26(4):595-608</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22193964</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Hematol Oncol. 2015 Sep 04;8:103</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26337806</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest New Drugs. 2015 Jun;33(3):652-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25777468</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Clin Pharmacol. 2015 May;79(5):789-800</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25377318</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Oncol. 2014 Apr;41(2):252-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24787296</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Support Care Cancer. 2010 Feb;18(2):151-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19381691</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood Cancer J. 2014 Oct 17;4:e251</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25325301</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2012 May 15;18(10):2954-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22394984</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cancer Res Clin Oncol. 2013 Apr;139(4):681-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23315099</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18762933</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Future Oncol. 2015;11(8):1153-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25832873</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pharmacol. 2016 Oct;56(10):1288-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26872892</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2014 Dec;15(13):1503-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25456369</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2014 Aug 14;124(7):1047-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24904120</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood Cancer J. 2015 Aug 14;5:e338</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26275080</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>